Katharine N Bossart

Summary

Affiliation: Boston University
Country: USA

Publications

  1. doi request reprint Paramyxovirus entry
    Katharine N Bossart
    Department of Microbiology, Boston University School of Medicine, Boston, MA, USA
    Adv Exp Med Biol 790:95-127. 2013
  2. pmc A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection
    Katharine N Bossart
    CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong, Victoria, Australia
    PLoS Pathog 5:e1000642. 2009
  3. pmc A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge
    Katharine N Bossart
    Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA
    Sci Transl Med 4:146ra107. 2012
  4. doi request reprint A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats
    Jennifer A McEachern
    CSIRO Livestock Industries, Australian Animal Health Laboratory, 5 Portarlington Road, Geelong, Victoria 3220, Australia
    Vaccine 26:3842-52. 2008
  5. ncbi request reprint Functional studies of host-specific ephrin-B ligands as Henipavirus receptors
    Katharine N Bossart
    CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong, Victoria 3220, Australia
    Virology 372:357-71. 2008
  6. pmc Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, Massachusetts, United States of America
    PLoS ONE 5:e10690. 2010
  7. ncbi request reprint Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems
    Katharine N Bossart
    CSIRO Livestock Industries, Australian Animal Health Laboratory, 5 Portarlington Road, Geelong, VIC 3220, Australia
    J Virol Methods 142:29-40. 2007
  8. pmc A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge
    Katharine N Bossart
    Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA
    Sci Transl Med 3:105ra103. 2011
  9. pmc Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virus
    Michelle L Colgrave
    Queensland Bioscience Precinct, CSIRO Livestock Industries, St Lucia, QLD 4067, Australia
    Glycobiology 22:572-84. 2012
  10. pmc Serotype-specific host responses in rhesus macaques after primary dengue challenge
    Andrew C Hickey
    Department of Microbiology, National Emerging Infectious Diseases Laboratories Institute, Laboratory Animal Science Center, Boston University, Boston, Massachusetts Venture Technologies, Penang, Malaysia Sentinext Therapeutics, Penang, Malaysia
    Am J Trop Med Hyg 89:1043-57. 2013

Collaborators

Detail Information

Publications15

  1. doi request reprint Paramyxovirus entry
    Katharine N Bossart
    Department of Microbiology, Boston University School of Medicine, Boston, MA, USA
    Adv Exp Med Biol 790:95-127. 2013
    ..Finally, the different proposed fusion models are reviewed, featuring recent experimental findings that speculate how the attachment and fusion glycoproteins work in concert to mediate virus entry...
  2. pmc A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection
    Katharine N Bossart
    CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong, Victoria, Australia
    PLoS Pathog 5:e1000642. 2009
    ..This study is the first successful post-exposure passive antibody therapy for Nipah virus using a human monoclonal antibody...
  3. pmc A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge
    Katharine N Bossart
    Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA
    Sci Transl Med 4:146ra107. 2012
    ..Success of the recombinant subunit vaccine in nonhuman primates provides crucial data in supporting its further preclinical development for potential human use...
  4. doi request reprint A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats
    Jennifer A McEachern
    CSIRO Livestock Industries, Australian Animal Health Laboratory, 5 Portarlington Road, Geelong, Victoria 3220, Australia
    Vaccine 26:3842-52. 2008
    ..The ability to elicit protective systemic and mucosal immunity in this animal model provides significant progress towards the development of a human subunit vaccine against henipaviruses...
  5. ncbi request reprint Functional studies of host-specific ephrin-B ligands as Henipavirus receptors
    Katharine N Bossart
    CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong, Victoria 3220, Australia
    Virology 372:357-71. 2008
    ....
  6. pmc Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, Massachusetts, United States of America
    PLoS ONE 5:e10690. 2010
    ....
  7. ncbi request reprint Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems
    Katharine N Bossart
    CSIRO Livestock Industries, Australian Animal Health Laboratory, 5 Portarlington Road, Geelong, VIC 3220, Australia
    J Virol Methods 142:29-40. 2007
    ..Sera from henipavirus-seropositive animals differentially blocked ephrin-B2 binding, suggesting that detection and differentiation of HeV and NiV neutralizing antibodies can be done simultaneously in the absence of live virus...
  8. pmc A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge
    Katharine N Bossart
    Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA
    Sci Transl Med 3:105ra103. 2011
    ..These results represent successful post-exposure in vivo efficacy by an investigational drug against HeV and highlight the potential impact a hmAb can have on human disease...
  9. pmc Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virus
    Michelle L Colgrave
    Queensland Bioscience Precinct, CSIRO Livestock Industries, St Lucia, QLD 4067, Australia
    Glycobiology 22:572-84. 2012
    ..The structural features of G protein glycosylation were also determined by X-ray crystallography and interactions with the ephrin-B2 receptor are discussed...
  10. pmc Serotype-specific host responses in rhesus macaques after primary dengue challenge
    Andrew C Hickey
    Department of Microbiology, National Emerging Infectious Diseases Laboratories Institute, Laboratory Animal Science Center, Boston University, Boston, Massachusetts Venture Technologies, Penang, Malaysia Sentinext Therapeutics, Penang, Malaysia
    Am J Trop Med Hyg 89:1043-57. 2013
    ..However, some heterotypic neutralizing activity was noted in infected animals. Identification of serotype-specific host responses may help elucidate mechanisms that mediate severe DENV disease after reinfection...
  11. doi request reprint Expression of novel genes encoded by the paramyxovirus J virus
    Philippa J M Jack
    CSIRO Livestock Industries, Australian Animal Health Laboratory, Private Bag 24 Geelong, Victoria 3220, Australia
    J Gen Virol 89:1434-41. 2008
    ..Preliminary studies indicate that the novel TM protein is a type II glycosylated integral membrane protein, orientated with its C terminus exposed at the cell surface...
  12. ncbi request reprint Serotype-independent detection of foot-and-mouth disease virus
    Janine D Muller
    CSIRO Livestock Industries, Australian Animal Health Laboratory, 5 Portarlington Road, Geelong, Victoria 3220, Australia
    J Virol Methods 151:146-53. 2008
    ....
  13. doi request reprint Host cell tropism mediated by Australian bat lyssavirus envelope glycoproteins
    Dawn L Weir
    Department of Microbiology, Uniformed Services University, Bethesda, MD 20814, USA
    Virology 444:21-30. 2013
    ..Proposed rabies virus receptors were not sufficient to permit ABLV entry into resistant cells, suggesting that ABLV utilizes an unknown alternative receptor(s). ..
  14. ncbi request reprint Developments towards effective treatments for Nipah and Hendra virus infection
    Katharine N Bossart
    Australian Animal Health Laboratory, CSIRO Livestock Industries, Geelong, Victoria 3220, Australia
    Expert Rev Anti Infect Ther 4:43-55. 2006
    ....
  15. pmc Targeted strategies for henipavirus therapeutics
    Katharine N Bossart
    CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong, Victoria 3220, Australia
    Open Virol J 1:14-25. 2007
    ..Assessments of protective host immunity and drug pharmacokinetics will be crucial to the further advancement of therapeutic compounds...